Hyperphosphatemia Drugs Market by Product Type, Distribution Channel, End User 2023-2028

1
Global Hyperphosphatemia Drugs Market Research
and Forecast Report 2023-2028

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Hyperphosphatemia Drugs Market Global
  Industry Trends, Share, Size, Growth, Opportunity
  and Forecast 2023-2028," the global
  hyperphosphatemia drugs market size reached US
  3.8 Billion in 2022.
• Hyperphosphatemia drugs are medications used to
  treat a medical condition called
  hyperphosphatemia, characterized by abnormally
  high levels of phosphate in the blood. Phosphate
  is an essential mineral that plays a crucial role
  in numerous physiological processes, such as bone
  formation, nerve function, and energy metabolism.
  
• These drugs work by reducing the absorption of
  phosphate from the gastrointestinal tract or
  promoting its elimination through the kidneys.
  One common class of drugs used for this purpose
  is phosphate binders. These medications bind to
  dietary phosphate in the digestive tract,
  preventing its absorption into the bloodstream.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/hyperphosphatemia-drugs
  -market/requestsample

4
Report Description

• Global Hyperphosphatemia Drugs Market Trends
• The increasing prevalence of chronic kidney
  disease (CKD) and end-stage renal disease (ESRD)
  is driving the global market. As the incidence of
  CKD and ESRD rises globally, so does the demand
  for drugs that can effectively manage and lower
  phosphate levels in the blood. Moreover, the
  growing aging population is contributing to the
  expansion of the hyperphosphatemia drugs market.
  Elderly individuals are more susceptible to
  kidney-related conditions, leading to a higher
  prevalence of hyperphosphatemia in this
  demographic. Additionally, continual advancements
  in medical research and drug development have led
  to the introduction of new and improved
  hyperphosphatemia drugs.
• Pharmaceutical companies are investing in
  research to develop novel medications that can
  provide better efficacy and fewer side effects,
  enhancing patient outcomes and driving market
  growth. Furthermore, the increasing awareness and
  diagnosis of hyperphosphatemia in patients with
  CKD and ESRD have also contributed to market
  expansion. Early detection and intervention are
  essential for managing the condition effectively,
  leading to a greater demand for appropriate
  pharmaceutical treatments.
• Looking forward, the market value is projected to
  reach US 6.1 Billion by 2028, expanding at a
  CAGR of 8.1 during 2023-2028.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/hyperphosphatemia-drugs
  -market

5
Report Segmentation

• Product Insights
• Sevelamer
• Calcium Based Phosphate Binders
• Iron Based Phosphate Binders
• Lanthanum Carbonate
• Others
•  
• Dosage Form Insights
• Tablets
• Syrups
• Capsules
• Distribution Channel Insights
• Hospital Pharmacies
• Retail Pharmacies

6
Report Segmentation

• Online Pharmacies
• Regional Insights
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7
Competitive Landscape with Key Players

• Ardelyx Inc.
• Fresenius Medical Care AG Co. KGaA
• Lupin Pharmaceuticals Inc (Lupin Limited)
• Torii Pharmaceutical Co. Ltd. (Japan Tobacco
  Inc.)
• Vifor Pharma Management Ltd. (CSL Limited)

8
Key Questions Answered in the Report
9
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Hyperphosphatemia
  Drugs Market    5.1    Market Overview    5.2  
   Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by Product    6.1   
  Sevelamer        6.1.1 Market Trends       
  6.1.2 Market Forecast    6.2    Calcium Based
  Phosphate Binders        6.2.1 Market Trends   
      6.2.2 Market Forecast    6.3    Iron Based
  Phosphate Binders        6.3.1 Market Trends   
      6.3.2 Market Forecast       

10
Table of Contents

•     6.4    Lanthanum Carbonate        6.4.1
  Market Trends        6.4.2 Market Forecast   
  6.5    Others        6.5.1 Market Trends       
  6.5.2 Market Forecast7    Market Breakup by
  Dosage Form    7.1    Tablets        7.1.1
  Market Trends        7.1.2 Market Forecast   
  7.2    Syrups        7.2.1 Market Trends       
  7.2.2 Market Forecast    7.3    Capsules       
  7.3.1 Market Trends        7.3.2 Market
  Forecast8    Market Breakup by Distribution
  Channel    8.1    Hospital Pharmacies       
  8.1.1 Market Trends        8.1.2 Market
  Forecast    8.2    Retail Pharmacies       
  8.2.1 Market Trends        8.2.2 Market
  Forecast    8.3    Online Pharmacies       
  8.3.1 Market Trends        8.3.2 Market
  Forecast
• For more information, visit https//www.imarcgrou
  p.com/hyperphosphatemia-drugs-market/toc

11
Disclaimer

• 2023 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

12
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE [phone] E-MAIL
sales_at_imarcgroup.com